Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Average Rating of “Buy” by Brokerages

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have received a consensus recommendation of “Buy” from the ten research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $20.33.

Several equities research analysts recently issued reports on AUPH shares. HC Wainwright set a $25.00 price objective on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, November 1st. BidaskClub upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 7th. Oppenheimer lifted their price objective on Aurinia Pharmaceuticals from $14.00 to $22.00 in a report on Thursday, December 5th. Bloom Burton reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 2nd. Finally, Cantor Fitzgerald lifted their price objective on Aurinia Pharmaceuticals from $24.00 to $30.00 in a report on Thursday, December 5th.

Shares of Aurinia Pharmaceuticals stock opened at $18.25 on Friday. Aurinia Pharmaceuticals has a twelve month low of $3.52 and a twelve month high of $18.88. The business has a 50-day moving average price of $7.52 and a 200 day moving average price of $6.34. The firm has a market cap of $1.74 billion, a PE ratio of -24.01 and a beta of 1.27.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, November 14th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 50.79% and a negative net margin of 19,483.96%. The firm had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.05 million. Sell-side analysts anticipate that Aurinia Pharmaceuticals will post -0.73 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of AUPH. Vivo Capital LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 57.7% during the 2nd quarter. Vivo Capital LLC now owns 1,913,623 shares of the biotechnology company’s stock worth $12,592,000 after purchasing an additional 700,333 shares during the last quarter. Orbimed Advisors LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 12.1% during the 2nd quarter. Orbimed Advisors LLC now owns 3,531,002 shares of the biotechnology company’s stock worth $23,234,000 after purchasing an additional 381,192 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Aurinia Pharmaceuticals during the 3rd quarter worth approximately $246,000. BlackRock Inc. boosted its holdings in shares of Aurinia Pharmaceuticals by 3.1% during the 2nd quarter. BlackRock Inc. now owns 921,425 shares of the biotechnology company’s stock worth $6,063,000 after purchasing an additional 28,129 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Aurinia Pharmaceuticals during the 3rd quarter worth approximately $122,000. Institutional investors and hedge funds own 32.06% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Story: Short Selling Stocks, A Beginner’s Guide

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.